Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025
Summary
HR 6894 is an early-stage, low-probability bill that expands Medicare cardiac and pulmonary rehab supervision to PAs, NPs, and CNSs. It authorizes zero funding and remains in committee. Marginal upside for healthcare staffing firm AMN (allied health demand) is possible but contingent on passage. Labcorp (LH) sees no structural impact. Current market prices: AMN $20.62, LH $262.99.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 6894 is a low-probability, early-stage scope-of-practice bill with zero authorized funding.
- 2.AMN Healthcare ($AMN) has marginal upside if bill passes, via expanded demand for mid-level practitioners in cardiac rehab.
- 3.Labcorp ($LH) is structurally unaffected; the bill does not alter lab testing or diagnostics coverage.
- 4.No current market pricing reflects this bill — AMN's 12.43% 30-day gain is from broader staffing recovery trends.
- 5.Passage requires referral through two House committees, floor votes in both chambers, and presidential action — unlikely in 2025-2027.
Market Implications
No actionable market impact today. AMN ($20.62) is already pricing in sector recovery independent of HR 6894. LH ($262.99) remains driven by diagnostic testing demand, competitive dynamics with Quest Diagnostics ($DGX), and reimbursement policy, not by this rehabilitation scope bill. Investors should monitor committee activity — a markup or hearing would be the first real signal of legislative momentum. Without one, this bill is noise for retail portfolios.
Full Analysis
What happened: On December 18, 2025, Rep. Sewell (D-AL) introduced HR 6894, the 'Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025.' The bill amends the Social Security Act to allow physician assistants, nurse practitioners, and clinical nurse specialists to prescribe exercise, prepare treatment plans, and supervise cardiac and pulmonary rehab programs under Medicare Part B. The bill was referred to both the Energy and Commerce and Ways and Means Committees. An identical companion bill (S717) exists in the Senate. The bill has only one cosponsor, Rep. Smith of Nebraska (R-NE), and has seen no further action since referral.
The money trail: This bill authorizes zero new funding. It is a scope-of-practice expansion, not an appropriations bill. It does not change Medicare reimbursement rates for rehab services, nor does it increase the number of covered sessions. The mechanism is purely regulatory — it expands the pool of practitioners who can independently manage these programs. Any revenue impact flows from increased patient throughput, not from new direct spending.
Structural winners and losers: The primary potential beneficiaries are healthcare staffing firms like AMN Healthcare ($AMN) that place mid-level practitioners. Expanded scope could increase demand for PAs/NPs in outpatient cardiac rehab settings. Labcorp is listed but has minimal direct exposure — the bill does not alter lab testing requirements or coverage. Larger healthcare systems and hospital chains (HCA, THC) could see marginal volume increases if implementation increases patient enrollment, but these effects are small and distant.
Real market data context: AMN trades at $20.62, up 12.43% over 30 days but still well below its 52-week high of $23.74. The recent uptrend appears driven by broader healthcare staffing recovery, not HR 6894. LH at $262.99 is down 1.43% over 30 days and 0.31% over 7 days, reflecting sector headwinds unrelated to this bill.
Timeline: The bill is in the earliest legislative stage with only one House cosponsor and no committee hearings. Passage probability in the 119th Congress is low given the narrow scope and absence of funding. The identical Senate companion (S717) adds minimal momentum. Procedural hurdles: House committee markup, floor vote, Senate committee, floor vote, and presidential signature remain, all requiring bipartisan cooperation in a divided Congress.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Scope-of-practice expansion: allows PAs, NPs, and CNSs to prescribe, supervise, and administer cardiac/pulmonary rehab programs in office settings under Medicare.
Who must act
Medicare-enrolled physician assistants, nurse practitioners, and clinical nurse specialists who choose to offer cardiac/pulmonary rehab services in their own offices.
What happens
Expands the pool of eligible prescribers and supervisors for these rehabilitation programs, potentially increasing patient access and the volume of billable rehab sessions. No new funding or reimbursement rate change is authorized.
Stock impact
AMN Healthcare ($AMN) supplies temporary allied health staff including PAs and NPs to hospitals and clinics. Expanded scope of practice could increase demand for mid-level practitioners in cardiac rehab roles, raising staffing contract revenue marginally. The 30-day price change of +12.43% already reflects broader sector momentum rather than this specific bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act of 2025
MEDLINE INDUSTRIES, LP: $77.6M Department of Veterans Affairs Contract
Improving Access to Care for Rural Veterans Act
Fast Track Healthcare Apprenticeships Act
SAFE Act
NORTH EAST SOUTH WEST HEALTHCARE SOLUTIONS, LLC: $16.5M Department of Homeland Security Contract
NATIONWIDE HEALTHCARE SOLUTIONS, LLC: $16.9M Department of Health and Human Services Contract
Veterans Community Care Scheduling Improvement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →